Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NCT07185204) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study
United States, Nepal60 participantsStarted 2026-05
Plain-language summary
The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pregnant patients ≥ 36 weeks gestation without major fetal anomalies
* Age ≥ 18 years
* Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital
* At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF
* 1 or more high risk factors:
* History of preeclampsia
* Type 1 or 2 diabetes
* Multifetal gestation?
* Renal disease
* Autoimmune disease
* 2 or more moderate risk factors:
* Nulliparity
* BMI \> 30
* First-degree relative with a history of preeclampsia
* African American race
* Low socioeconomic status
* Age \> 35 years
* History of low birthweight or small for gestational age
* Previous adverse pregnancy outcome
* Interpregnancy interval \> 10 years
Exclusion Criteria:
* Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
* Chronic hypertension, according to ACOG guidelines
* Known allergy or contraindication to nifedipine
* Inability or unwillingness to provide informed consent
* Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)